With the continuous efforts in research and development, novel therapies in the major depressive disorder pipeline such as AXS-05 (Axsome Therapeutics), Travivo (Fabre-Kramer Pharmaceuticals), SAGE-217 (SAGE Therapeutics), CAPLYTA  (Intra-Cellular Therapies), LY03005 (Luye Pharma), cariprazine (AbbVie), seltorexant (Minerva Neurosciences), REL-1017 (Relmada Therapeutics), and PH10 (VistaGen Therapeutics), are expected to enter the United States, EU5 (Germany, Italy, France, Spain, the United Kingdom) and Japan major depressive disorder market in next few years.